|

Afatinib Clinical Trials

11 actively recruiting trials across 1 location

Also known as: 30mg po qd, Gilotrif(Boehringer-Ingelheim), Gilotrif™, Giotrif, Targeted therapy

Pipeline

Early 1: 1Phase 1: 2Phase 2: 4Phase 1/2: 3

Top Sponsors

West China Hospital3
The Netherlands Cancer Institute1
Shanghai Jiao Tong University School of Medicine1
National University Hospital, Singapore1
Massachusetts General Hospital1

Indications

Cancer11
Targeted Therapy3
Immunotherapy3
Lysogenic HSV Virus2
HNSCC2

Other10 trials

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Phase 1

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Phase 2

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Phase 1/2

Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1/2

Observational Study of Afatinib 30 mg Daily

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase 2

Pilot Trial for Treatment of Recurrent Glioblastoma

Early 1

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Phase 1/2

Boston, Massachusetts1 trial

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.